OMA Guidelines Bundle

Obesity Pharmacotherapy - Obesity Algorithm 2024

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1349812

Contents of this Issue

Navigation

Page 11 of 33

12 Anti-obesity Pharmacotherapy Anti-obesity Medication Summary Agent/Dose Description Main Side Effects/ Adverse Reactions Orlistat (Alli ® , Xenical ® ) Capsule to be taken with meals 60–120 mg PO TID • Gastrointestinal lipase inhibitor that impairs digestion of dietary fat. Lower doses are approved over-thecounter. • Average reported weight loss of 5%. Oily stools and flatus, especially after fatty foods. Can promote gallstones and kidney stones and malabsorption of fat- soluble vitamins (A, D, E, K). A multivitamin daily is recommended. Rare cases of severe liver injury and pancreatitis have been reported (cont'd)

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy - Obesity Algorithm 2024